• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 8, Issue 3
  3. Author

Online ISSN: 2515-8260

Volume8, Issue3

A STUDY TO EVALUATE THE EFFECTIVENESS OF ANTIHYPERTENSIVE DRUGS ON NEWLY DIAGNOSED HYPERTENSIVE PATIENTS IN ASSOCIATION WITH ACE GENE POLYMORPHISM

    Madhu Chaitanya Thota, Dr. Nilam Nigam, Dr. Shravan Kumar, Dr. Anil Kumar

European Journal of Molecular & Clinical Medicine, 2021, Volume 8, Issue 3, Pages 2230-2239

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Background: Essential hypertension is among such lifestyle diseases which are the leading causes of premature deaths around the globe, due to their cardiovascular and kidney disease complications, if remains untreated. Angiotensin converting enzyme gene I/D polymorphism has been found to affect hypertension and the response of antihypertensive therapies.
Materials and Methods: This is prospective and cross-sectional study.
In Group – A:  ACE gene polymorphism in hypertension
a)  Azilsartan (40-80mg)
b)  Atenolol (25-100mg)
c)  Chlorthalidone (12.5-25mg)
Result: In our study baseline, systolic blood pressure was 172.31 mmHg Atenolol group, 179.94 mmHg Azilsartan group and in Chlorthalidone was 177.48 mmHg. Baseline Diastolic Blood pressure was 101.43 mmHg in Atenolol group, 103.78 mmHg in Azilsartan group and in Chlorthalidone was 109.59 mmHg. While comparing among 3 groups baseline blood pressure was statistically not significant. After 3 months of treatment with Atenolol group, 163.42 mmHg, in Azilsartan group 167.47 mmHg and in Chlorthalidone was 169.47 mmHg systolic blood pressure. Baseline Diastolic Blood pressure was 98.48 mmHg in Atenolol group, 97.58 mmHg in Azilsartan group and in Chlorthalidone was 98.37 mmHg. While comparing among 3 groups after 3 months blood pressure was statistically significant.
Conclusion: Angiotensin Converting Enzyme (ACE) gene polymorphism is linked to isolated systolic hypertension (ISH). Renin-Angiotensin-Aldosterone-System (RAAS) is one of the regulatory systems governing circulation, systemic vascular resistance, and kidney function.
Keywords: Antihypertensive drugs, Hypertensive patients, Ace gene polymorphism.
 
Keywords:
  • PDF (195 K)
  • XML
(2021). A STUDY TO EVALUATE THE EFFECTIVENESS OF ANTIHYPERTENSIVE DRUGS ON NEWLY DIAGNOSED HYPERTENSIVE PATIENTS IN ASSOCIATION WITH ACE GENE POLYMORPHISM. European Journal of Molecular & Clinical Medicine, 8(3), 2230-2239.
Madhu Chaitanya Thota, Dr. Nilam Nigam, Dr. Shravan Kumar, Dr. Anil Kumar. "A STUDY TO EVALUATE THE EFFECTIVENESS OF ANTIHYPERTENSIVE DRUGS ON NEWLY DIAGNOSED HYPERTENSIVE PATIENTS IN ASSOCIATION WITH ACE GENE POLYMORPHISM". European Journal of Molecular & Clinical Medicine, 8, 3, 2021, 2230-2239.
(2021). 'A STUDY TO EVALUATE THE EFFECTIVENESS OF ANTIHYPERTENSIVE DRUGS ON NEWLY DIAGNOSED HYPERTENSIVE PATIENTS IN ASSOCIATION WITH ACE GENE POLYMORPHISM', European Journal of Molecular & Clinical Medicine, 8(3), pp. 2230-2239.
A STUDY TO EVALUATE THE EFFECTIVENESS OF ANTIHYPERTENSIVE DRUGS ON NEWLY DIAGNOSED HYPERTENSIVE PATIENTS IN ASSOCIATION WITH ACE GENE POLYMORPHISM. European Journal of Molecular & Clinical Medicine, 2021; 8(3): 2230-2239.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 172
  • PDF Download: 224
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus